Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.262
-0.023 (-8.04%)
At close: Apr 28, 2026, 4:00 PM EDT
0.265
+0.003 (1.11%)
After-hours: Apr 28, 2026, 6:23 PM EDT
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -83.33% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Outlook Therapeutics stock have an average target of 2.50, with a low estimate of 0.50 and a high estimate of 6.00. The average target predicts an increase of 853.83% from the current stock price of 0.26.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +2,189.20% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $0.5 | Hold | Reiterates | $0.5 | +90.77% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $1 | Hold | Maintains | $1 | +281.53% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +281.53% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.5 | Hold | Maintains | $1 → $0.5 | +90.77% | Jan 2, 2026 |
Financial Forecast
Revenue This Year
21.64M
from 1.41M
Increased by 1,430.98%
Revenue Next Year
59.13M
from 21.64M
Increased by 173.23%
EPS This Year
-0.53
from -1.79
EPS Next Year
-0.35
from -0.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 48.3M | 139.3M | ||||||
| Avg | 21.6M | 59.1M | ||||||
| Low | 8.5M | 15.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3,318.6% | 543.6% | ||||||
| Avg | 1,431.0% | 173.2% | ||||||
| Low | 498.1% | -26.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.44 | -0.22 | ||||||
| Avg | -0.53 | -0.35 | ||||||
| Low | -0.61 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.